Cardiology

The virtual sessions will cover a litany of topics in the greater spectrum of cardiovascular disease prevention and care.

Data show SGLT2is reduced HHF in patients with both stablished HFrEF and CKD and are likely to also be effective in patients with HFpEF.

Data from COMPASS show adding low-dose low-dose rivaroxaban to aspirin resulted in benefits regardless of number of concomitant drugs or comorbidities.

Cardiac monitoring has not been adequately established for such patients.

Novartis announced the Complete Response resubmission for inclisiran in a statement on July 6, 2021.

Dr. Manesh Patel shares perspective on the "renaissance of anti-thrombotic therapy" for patients at risk of cardiovascular events.

Our latest cardiology case report from Brady Pregerson, MD, features a man in his 20s presenting to the emergency department complaining of body aches, chest discomfort, and light-headedness. Can you determine the correct diagnosis?

Schuyler Jones, MD discusses risk stratification in CAD/PAD and treatments aimed at atherothrombosis.

Growing evidence shows promise of stroke prevention with anti-thrombotic therapy in patients with AF.

The EMPEROR-Preserved trial demonstrated safety and efficacy of empagliflozin for patients with heart failure across spectrum of ejection fraction.

June's month in review features stories related to myocarditis-like illnesses associated with mRNA vaccines, an AHA recommendation for prescribing physical activity, and some highs and lows for Medtronic medical devices. Check back around the end of each month for the next Cardiology Month in Review.

Dr. Paul Thompson reflects on the cardiology's community journey of understanding related to coronary plaque, sudden cardiac death, and acute coronary syndromes.

Insights from the DISCOVER registry were presented at the American Diabetes Association's 81st Scientific Sessions. Check out our Q&A with study presenter Suzanne Arnold, MD, of St. Luke's Mid America Heart Institute.

Marc Bonaca, MD, discusses a new analysis of the VOYAGER PAD trial and implications for patients with diabetes and CLI.

Dennis Bruemmer, MD discusses new agents and perspectives on care in treating patients with type 2 diabetes at high risk of CV, renal complications.

Mortality rates differed significantly across the 3 clusters.

A dive into data from the RAND Health and Retirement Study suggests changes in wealth mobility, whether positive or negative, were associated with changes in cardiovascular disease risk.

While still waiting for regulatory approval, the SCORED and SOLOIST trial have demonstrated the impact of sotagliflozin, a dual SGLT1/2 inhibitor, on patients with type 2 diabetes and chronic kidney disease or heart failure.

Data from the AMPLITUDE-O trial demonstrates the effects of the exendin-4-based GLP-1 RA efpeglenatide on cardiovascular and renal outcomes among patients with type 2 diabetes and cardiovascular disease or kidney disease.

Deepak Bhatt, MD, MPH, discusses the results of REDUCE-IT BMI, which examined effects of icosapent ethyl vs placebo based on baseline BMI, that he presented at ADA 2021.

Marc P. Bonaca, MD, MPH, of the University of Colorado School of Medicine, comments on the potential to personalize treatment with emerging therapies in the pipeline to better manage patients at high risk for cardiovascular disease in the future.

Unmet needs in the management of coronary artery disease and peripheral artery disease, and advice for working with patients and other healthcare professionals to optimize care for patients at high risk for cardiovascular disease.

Matthew Budoff, MD highlights his own preferred methods of treatment and what might need to be done to help doctors and patients through the process.

Data show a 38% reduction in T2D incidence with dapagliflozin compared to placebo in patients with CKD.

Data show 66% of healthcare professionals reported greater confidence in prescribing SGLT2i, while 55% reported greater confidence in prescribing GLP-1.